acarbose vs insulin lispro
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acarbose and insulin lispro. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Precose
Humalog
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes. It works best when used with diet and exercise.
Admelog is a rapid-acting insulin that helps control blood sugar levels. It is used to treat diabetes in adults and children.
Acarbose is used to help control blood sugar in adults with type 2 diabetes. You should use it along with a healthy diet and regular exercise. This medicine helps to keep your blood sugar from getting too high after you eat.
Admelog is used to improve blood sugar control in people with diabetes. Diabetes is a disease where your body does not make enough insulin or cannot use insulin properly. This medicine helps your body use sugar from the food you eat.
Acarbose slows down the digestion of carbohydrates (sugars and starches) in your body. It does this by blocking certain enzymes in your small intestine that break down carbs. This helps to prevent a sharp rise in blood sugar after meals.
Admelog is a man-made insulin that works like the insulin your body should be making. It helps sugar move from your blood into your cells. This lowers your blood sugar levels.
- • Gas
- • Diarrhea
- • Abdominal pain
- • Common cold
- • Upper respiratory infection
- Hypoglycaemia 269
- Nausea 203
- Blood Glucose Increased 200
- Dizziness 160
- Diarrhoea 147
- Blood Glucose Increased 38,180
- Incorrect Dose Administered 9,067
- Blood Glucose Decreased 8,761
- Visual Impairment 5,392
- Nausea 4,787
You should not take acarbose if you have diabetic ketoacidosis or cirrhosis. Also, do not take it if you have inflammatory bowel disease, colon ulcers, or any bowel obstruction. This medicine can cause liver problems in some people. Tell your doctor right away if you develop symptoms like yellowing of the skin or eyes.
Never share your Admelog SoloStar pen or syringe with anyone else, even if you change the needle. Sharing can spread blood-borne diseases. Changes in your insulin plan can cause high or low blood sugar. Make these changes carefully with your doctor's help. Low blood sugar can be life-threatening. Watch your blood sugar closely.
Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acarbose will harm your unborn baby. Talk to your doctor if you are breastfeeding or plan to breastfeed. It is not known if acarbose passes into breast milk.
Talk to your doctor if you are pregnant or plan to become pregnant. Poorly controlled diabetes during pregnancy can harm both the mother and the baby. Discuss the risks and benefits of using Admelog with your doctor if you are breastfeeding.
Also Compare, Nearby Drugs
Compare acarbose with
Compare insulin lispro with
How to Read This acarbose vs insulin lispro Comparison
acarbose is classified in the Alpha-Glucosidase Inhibitor drug class, while insulin lispro sits within the Rapid-Acting Insulin class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acarbose has 979 submissions while insulin lispro has 66,187. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acarbose or insulin lispro.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.